§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇲🇽Mexico No fee amount confirmed	🇪🇺European Union Fees verified 12 September 2026
Authority & dossier
Fee confirmation	No fee amount confirmed	Fees verified 12 September 2026
Regulatory authority	COFEPRIS	EMA
English submissions	No	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA, EMA, Health Canada, Swissmedic +5	Not stated
Lead pathway (timeline & fees), Registro Sanitario, Modalidad A (New Molecule) · Centralised Procedure
Pathway name	Registro Sanitario, Modalidad A (New Molecule)	Centralised Procedure
Approval timeline	240-365 days	210-277 days
Headline fee and pathway	Fees not covered	EUR 865,200, Centralised Procedureconditional on other
Recurring charges	Fees not covered	EUR 232,400 a year, per marketing authorisation, other applications
Local representative	Required	Required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	A Responsable Sanitario (Sanitary Responsible, typically a licensed pharmacist or QFB) must be designated and listed in the Aviso de Responsable Sanitario. A separate Responsable de Farmacovigilancia (RFV) must be designated under NOM-220-SSA1-2016 with their own Aviso filed with COFEPRIS.	Qualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	3 designations	6 designations
Examples	Abbreviated Pathway (July 2025 Agreement), CMN Priority Designation, Public-Health Emergency Authorisation	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Modificaciones a las Condiciones de Registro Sanitario classified by COFEPRIS into administrative, technical (minor and major), and notifications. Major technical changes (manufacturing site, formulation, indication) require COFEPRIS approval; minor changes follow a notification procedure.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	Registro Sanitario valid for 5 years; renewal application (prórroga) must be filed within the 150 calendar days before expiry per RIS Article 376. Renewal requires updated safety information, marketing status confirmation and renewal fee.	Initial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	Pharmacovigilance regulated by NOM-220-SSA1-2016 and its 2020 amendment. Mandatory ICSR reporting to COFEPRIS (15-day for serious unlisted, periodic for others), PSUR/PBRER per ICH E2C(R2), Risk Management Plan for new molecules and biocomparables, and an in-country Responsable de Farmacovigilancia. Mexico is a WHO-UMC member contributing to VigiBase.	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-120 days	60-106 days
GCP standard	ICH-GCP E6(R2); aligned with Mexican Reglamento de la Ley General de Salud en Materia de Investigación para la Salud	ICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	Yes
HTA required	Yes	Yes
HTA body	Centro Nacional de Excelencia Tecnológica en Salud (CENETEC), HTA support to the Consejo de Salubridad General (CSG) for Cuadro Básico decisions	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

MexicoNo fee amount confirmed
European UnionFees verified 12 September 2026

Regulatory authority

MexicoCOFEPRIS
European UnionEMA

English submissions

MexicoNo
European UnionYes

CTD accepted

MexicoYes
European UnionYes

eCTD accepted

MexicoYes
European UnionYes

Reliance pathway

MexicoAvailable
European UnionAvailable

Reference agencies

MexicoFDA, EMA, Health Canada, Swissmedic +5
European UnionNot stated

Lead pathway (timeline & fees), Registro Sanitario, Modalidad A (New Molecule) · Centralised Procedure

Pathway name

MexicoRegistro Sanitario, Modalidad A (New Molecule)
European UnionCentralised Procedure

Approval timeline

Mexico240-365 days
European Union210-277 days

Headline fee and pathway

MexicoFees not covered
European UnionEUR 865,200, Centralised Procedureconditional on other

Recurring charges

MexicoFees not covered
European UnionEUR 232,400 a year, per marketing authorisation, other applications

Local representative

MexicoRequired
European UnionRequired

Local manufacturing

MexicoNot required
European UnionNot required

GMP inspection

MexicoRequired
European UnionRequired

MAH & local presence

Local entity required

MexicoYes
European UnionYes

Local responsible person

MexicoYes
European UnionYes

RP role

MexicoA Responsable Sanitario (Sanitary Responsible, typically a licensed pharmacist or QFB) must be designated and listed in the Aviso de Responsable Sanitario. A separate Responsable de Farmacovigilancia (RFV) must be designated under NOM-220-SSA1-2016 with their own Aviso filed with COFEPRIS.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

Mexico3 designations
European Union6 designations

Examples

MexicoAbbreviated Pathway (July 2025 Agreement), CMN Priority Designation, Public-Health Emergency Authorisation
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

MexicoModificaciones a las Condiciones de Registro Sanitario classified by COFEPRIS into administrative, technical (minor and major), and notifications. Major technical changes (manufacturing site, formulation, indication) require COFEPRIS approval; minor changes follow a notification procedure.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

MexicoRegistro Sanitario valid for 5 years; renewal application (prórroga) must be filed within the 150 calendar days before expiry per RIS Article 376. Renewal requires updated safety information, marketing status confirmation and renewal fee.
European UnionInitial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

MexicoPharmacovigilance regulated by NOM-220-SSA1-2016 and its 2020 amendment. Mandatory ICSR reporting to COFEPRIS (15-day for serious unlisted, periodic for others), PSUR/PBRER per ICH E2C(R2), Risk Management Plan for new molecules and biocomparables, and an in-country Responsable de Farmacovigilancia. Mexico is a WHO-UMC member contributing to VigiBase.
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

MexicoAvailable
European UnionAvailable

Compassionate Use

MexicoAvailable
European UnionAvailable

Emergency Import

MexicoAvailable
European UnionAvailable

Parallel Import

MexicoNot permitted
European UnionPermitted

Clinical trials

CTA approval

MexicoRequired
European UnionRequired

Ethics approval

MexicoYes
European UnionYes

CTA timeline

Mexico60-120 days
European Union60-106 days

GCP standard

MexicoICH-GCP E6(R2); aligned with Mexican Reglamento de la Ley General de Salud en Materia de Investigación para la Salud
European UnionICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

MexicoRegulated
European UnionRegulated

Reference pricing

MexicoYes
European UnionYes

HTA required

MexicoYes
European UnionYes

HTA body

MexicoCentro Nacional de Excelencia Tecnológica en Salud (CENETEC), HTA support to the Consejo de Salubridad General (CSG) for Cuadro Básico decisions
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)